Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.
Roche had 2 drugs approved by the FDA—one for a rare blood disease and the other for first-line treatment for lung cancer.
Zelboraf (vemurafenib) is the first FDA-approved drug for Erdheim-Chester disease (ECD), a rare blood disorder. The drug is already approved for the treatment of people with unresectable or metastatic melanoma with the BRAF V600E mutation. The FDA has now approved it specifically for patients with ECD who have the BRAF V600 mutation. ECD is characterized by the abnormal multiplication of histiocytes. These white blood cells can invade normal tissues and organs.
The drug was approved based on date from the phase 2 VE-BASKET study, which used the innovative clinical trial design matched a disease’s underlying genetic profile to the mechanism of action of the medicine. For the 22 people with ECD, the trial showed a best overall response rate of 54.5%.
“This FDA decision means people living with Erdheim-Chester disease will now, for the first time, have an FDA-approved treatment option,” Sandra Horning, MD, Roche’s chief medical officer and Head of Global Product Development, said in a statement. “We are committed to finding new ways to bring medicines to patients with high unmet need, and we are pleased that this innovative clinical trial helped identify Zelboraf for treatment of this rare disease.”
The second drug approved was Alecensa (alectinib) as a first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non—small cell lung cancer (NSCLC). The FDA approved the drug based on results from the phase 3 ALEX study, which showed the drug reduced the risk of disease worsening or death by 47% compared with crizotinib. Median progression-free survival was 25.7 months for people on alectinib compared with 10.4 months for those on crizotinib.
Alectinib has been recommended in the National Comprehensive Cancer Network guidelines as a treatment option for first-line ALK-positive metastatic NSCLC.
“Our goal is to develop medicines that have the potential to significantly improve upon the standard of care,” Horning said in a separate statement. “In our pivotal study, Alecensa significantly extended the time that people lived without their disease worsening compared to crizotinib and also showed a marked reduction in the risk of their cancer spreading to the brain.”
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More